Hydroxychloroquine use in patients with primary immune thrombocytopenia and antiphospholipid antibodies

The prevalence of antiphospholipid antibodies (aPL) among patients with immune thrombocytopenia (ITP) is high, at 20 % or higher according to previous studies [1,2].